Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN'S MHLW.CHUGAI PHARMACEUTICAL CO LTD-BASED ON RESULTS FROM PHASE I/III IMPOWER133 STUDY, TECENTRIQ WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF OVERALL SURVIVAL.
June 27 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::CHUGAI PHARMACEUTICAL - CHUGAI OBTAINS APPROVAL OF FOUNDATIONONE CDX CANCER GENOMIC PROFILE AS A COMPANION DIAGNOSTIC FOR ROZLYTREK.
Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::ALEXION - RESPONDING TO COMPLAINT FILED AGAINST CO BY CHUGAI PHARMACEUTICAL, CO TO OPPOSE CLAIMS & TO PROCEED WITH BUSINESS PLANS FOR ALXN1210.
Oct 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says the company announced that it has filed a lawsuit to the Tokyo District Court as of October 12, and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection), against Pfizer Japan Inc., the marketing authorization holder of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patent owned by Genentech, a member of the Roche group, as the ground.
Sept 27 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Chugai Pharmaceutical and Eli Lilly and Company today announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist .OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes.Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833 .Chugai will receive an upfront payment of $50 million and is eligible for milestone payments based on achievement of certain predetermined milestones.If the molecule is successfully commercialized, Chugai would also be eligible for royalty payments.
Sept 26 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::SAYS CHUGAI AND LILLY ENTER INTO A LICENSE AGREEMENT FOR ORAL GLP-1 AGONIST, OWL833.CHUGAI'S ORAL GLP-1 AGONIST, OWL833, WILL SOON ENTER PHASE I CLINICAL DEVELOPMENT.UNDER THE TERMS OF THE AGREEMENT, LILLY WILL RECEIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO OWL833.CHUGAI PHARMACEUTICAL WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION AND IS ELIGIBLE FOR MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF PREDETERMINED MILESTONES.AFTER TRANSACTION, THERE WILL BE NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE.CHUGAI PHARMACEUTICAL - THERE WILL BE NO CHANGE TO CO'S CONSOLIDATED FINANCIALS FORECAST FOR FY ENDING DECEMBER 2018 AS A RESULT OF THAT TRANSACTION.
June 26 (Reuters) - Pharma Mar SA <PHMR.MC>::SAYS IT HAS ENTERED INTO MUTUAL EARLY TERMINATION AGREEMENT WITH CHUGAI.REGAINS ITS RIGHTS FOR ZEPSYRE IN JAPAN AND WILL RECEIVE 3.0 MILLION EUROS FROM CHUGAI FOR EARLY TERMINATION.SAYS PROGRESSES IN CLINICAL DEVELOPMENT OF ZEPSYRE IN JAPAN.SAYS ITS ATLANTIS GLOBAL REGISTRATION TRIAL IN SMALL-CELL LUNG CANCER CONTINUES.
April 27 (Reuters) - Pharma Mar SA <PHMR.MC>::SAYS SUBMITS INFORMATION REGARDING THE TERMINATION OF THE LICENSING AGREEMENT FOR JAPAN ENTERED INTO WITH CHUGAI IN RELATION TO ZEPSYRE.EFFECTIVE DATE OF TERMINATION IS IN APRIL 2019.TERMINATION DOES NOT AFFECT ANY PAYMENTS RECEIVED BY PHARMAMAR.TO INITIATE NEGOTIATIONS IN THE SHORT TERM WITH OTHER POTENTIAL LICENSEES FOR ZEPSYRE IN JAPAN.TO CONTINUE WITH PHASE I CLINICAL TRIALS INITIATED IN JAPAN IN 2017 FOR JAPANESE PATIENTS.
April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc.
Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit.